Literature DB >> 30738807

Matrine ameliorates anxiety and depression-like behaviour by targeting hyperammonemia-induced neuroinflammation and oxidative stress in CCl4 model of liver injury.

Adnan Khan1, Bushra Shal1, Muhammad Naveed1, Fawad Ali Shah2, Ayesha Atiq1, Naseem Ullah Khan1, Yeong Shik Kim3, Salman Khan4.   

Abstract

Acute or chronic liver injury is associated with hyperammonemia which induced neuroinflammation and oxidative stress in the brain. Neuroinflammation, oxidative stress, reduced neurogenesis, and apoptosis are critical factors for the development of anxiety and depression. The present study was aimed to evaluate the anxiolytic and antidepressant properties of matrine against acute liver injury in the rodent model. Acute liver injury in mice was induced by administration of the acute hepatotoxic dose of carbon tetrachloride (CCl4) (1 ml/kg, i.p.). Pretreatment of mice with matrine (50 mg/kg i.p.) remarkably ameliorated CCl4-induced anxiety and depression-like behavior as evident from the results of open field test (OFT), elevated plus maze test (EPM), light-dark box test (LDB), forced swimming test (FST), and tail suspension test (TST). Moreover, matrine significantly inhibited CCl4-induced neuroinflammation in mice by reducing pro-inflammatory cytokines such as interleukins (IL-1β, IL-6) and tumor necrosis factor-α (TNF-α) levels in the hippocampus (HC) and prefrontal cortex (PFC). CCl4-induced oxidative stress was reduced by matrine due to its potential to enhance the levels of reduced glutathione (GSH), catalase (CAT), glutathione-S-transferase (GST), and decreased the malondialdehyde (MDA), and nitrite level in the PFC and HC of mice brain. Matrine remarkably reduced the levels of corticosterone, ammonia, AST, ALT, and creatinine. Matrine pretreatment remarkably ameliorated CCl4-induced morphological liver injury. Acute pretreatment of matrine enhanced neurogenesis by increasing the number of GFAF (glial fibrillary acidic protein) positive astrocyte, BDNF (brain-derived neurotrophic factor), and VEGF (vascular endothelial growth factor) in the hippocampus of CCl4-treated mice. Pretreatment of matrine inhibited apoptosis and DNA damage in the hippocampus. The present data revealed that hyperammonemia produced due to liver injury induced oxidative stress, neuroinflammation, reduced neurogenesis and apoptosis in the hippocampus, thus, resulting in anxiety and depression. Taken together, the present results suggested that matrine has a significant antidepressant and anxiolytic effects through modulation of neuroinflammation, oxidative stress, reduced neurogenesis and apoptosis induced by CCl4 administration.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; CCl4; Cytokines; Depression; Matrine; Oxidative stress

Mesh:

Substances:

Year:  2019        PMID: 30738807     DOI: 10.1016/j.neuro.2019.02.002

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  20 in total

1.  Anti-neuropathic pain activity of a cationic palladium (II) dithiocarbamate by suppressing the inflammatory mediators in paclitaxel-induced neuropathic pain model.

Authors:  Muhammad Naveed; Rahim Ullah; Adnan Khan; Bushra Shal; Ashraf Ullah Khan; Shahan Zeb Khan; Zia Ur Rehman; Salman Khan
Journal:  Mol Biol Rep       Date:  2021-11-03       Impact factor: 2.316

2.  Inflammatory state and autism-like behavioral phenotype of offspring induced by maternal exposure to low-dose chemical mixtures during pregnancy in mice.

Authors:  Linyang Song; Wenzhi Wen; Jing Liu; Xiaobao Jin; Junhua Yang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-06-25

3.  Synthesis, In Silico and Pharmacological Evaluation of New Thiazolidine-4-Carboxylic Acid Derivatives Against Ethanol-Induced Neurodegeneration and Memory Impairment.

Authors:  Shagufta Naz; Lina Tariq Al Kury; Humaira Nadeem; Fawad Ali Shah; Aman Ullah; Rehan Zafar Paracha; Muhammad Imran; Shupeng Li
Journal:  J Inflamm Res       Date:  2022-06-25

4.  Suppression of NF-κB signaling by ECN in an arthritic model of inflammation.

Authors:  Amna Khan; Li Zhang; Chang Hu Li; Ashraf Ullah Khan; Bushra Shal; Adnan Khan; Sajjad Ahmad; Fakhar Ud Din; Zia Ur Rehman; Feng Wang; Salman Khan
Journal:  BMC Complement Med Ther       Date:  2022-06-13

5.  Benzimidazole Derivatives as New Potential NLRP3 Inflammasome Inhibitors That Provide Neuroprotection in a Rodent Model of Neurodegeneration and Memory Impairment.

Authors:  Aman Ullah; Lina Tariq Al Kury; Yusuf S Althobaiti; Tahir Ali; Fawad ALi Shah
Journal:  J Inflamm Res       Date:  2022-07-11

6.  Suppression of TRPV1/TRPM8/P2Y Nociceptors by Withametelin via Downregulating MAPK Signaling in Mouse Model of Vincristine-Induced Neuropathic Pain.

Authors:  Adnan Khan; Bushra Shal; Ashraf Ullah Khan; Rahim Ullah; Muhammad Waleed Baig; Ihsan Ul Haq; Eun Kyoung Seo; Salman Khan
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

Review 7.  Matrine: A Promising Natural Product With Various Pharmacological Activities.

Authors:  Hong Zhang; Linlin Chen; Xipeng Sun; Quanjun Yang; Lili Wan; Cheng Guo
Journal:  Front Pharmacol       Date:  2020-05-07       Impact factor: 5.810

8.  Benzimidazole Containing Acetamide Derivatives Attenuate Neuroinflammation and Oxidative Stress in Ethanol-Induced Neurodegeneration.

Authors:  Muhammad Imran; Lina Tariq Al Kury; Humaira Nadeem; Fawad Ali Shah; Muzaffar Abbas; Shagufta Naz; Arif-Ullah Khan; Shupeng Li
Journal:  Biomolecules       Date:  2020-01-08

9.  Succinamide Derivatives Ameliorate Neuroinflammation and Oxidative Stress in Scopolamine-Induced Neurodegeneration.

Authors:  Sumbal Iqbal; Fawad Ali Shah; Komal Naeem; Humaira Nadeem; Sadia Sarwar; Zaman Ashraf; Muhammad Imran; Tariq Khan; Tayyaba Anwar; Shupeng Li
Journal:  Biomolecules       Date:  2020-03-13

Review 10.  An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events.

Authors:  Marika Cordaro; Salvatore Cuzzocrea; Rosalia Crupi
Journal:  Antioxidants (Basel)       Date:  2020-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.